President implored Republicans to make a better case for how much prices are easing in America ahead of next year's mid-term ...

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

I also own Eli Lilly, too, so I can handle that pain. Lilly may have the greatest drug franchise of all time with this GLP-1 ...

U.S. stocks rallied over the trading week, shortened by the Thanksgiving holiday and a reduced trading session on Friday. The ...

Meanwhile, Mercado Envíos (the logistics network) provides faster shipping that boosts customer satisfaction and incentivizes ...

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.